BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 25496490)

  • 1. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
    Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
    Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
    Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
    J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
    Epstein Shochet G; Wollin L; Shitrit D
    Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
    Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
    Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib.
    Epstein Shochet G; Brook E; Eyal O; Edelstein E; Shitrit D
    Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1025-L1034. PubMed ID: 30810067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
    Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
    Sato S; Shinohara S; Hayashi S; Morizumi S; Abe S; Okazaki H; Chen Y; Goto H; Aono Y; Ogawa H; Koyama K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
    Respir Res; 2017 Sep; 18(1):172. PubMed ID: 28915889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
    Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
    Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis.
    Grimminger F; Günther A; Vancheri C
    Eur Respir J; 2015 May; 45(5):1426-33. PubMed ID: 25745048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
    Liu F; Wang L; Qi H; Wang J; Wang Y; Jiang W; Xu L; Liu N; Zhuang S
    Clin Sci (Lond); 2017 Aug; 131(16):2125-2143. PubMed ID: 28646122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells.
    Li M; Ping G; Plathow C; Trinh T; Lipson KE; Hauser K; Krempien R; Debus J; Abdollahi A; Huber PE
    BMC Cancer; 2006 Mar; 6():79. PubMed ID: 16556328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basic FGF and PDGF-BB synergistically stimulate hyaluronan and IL-6 production by orbital fibroblasts.
    Virakul S; Heutz JW; Dalm VA; Peeters RP; Paridaens D; van den Bosch WA; Hirankarn N; van Hagen PM; Dik WA
    Mol Cell Endocrinol; 2016 Sep; 433():94-104. PubMed ID: 27267669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Mechanisms for the Antifibrotic Action of Nintedanib.
    Rangarajan S; Kurundkar A; Kurundkar D; Bernard K; Sanders YY; Ding Q; Antony VB; Zhang J; Zmijewski J; Thannickal VJ
    Am J Respir Cell Mol Biol; 2016 Jan; 54(1):51-9. PubMed ID: 26072676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats.
    Gad ES; Salama AAA; El-Shafie MF; Arafa HMM; Abdelsalam RM; Khattab M
    Inflammation; 2020 Feb; 43(1):123-134. PubMed ID: 31646446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
    Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
    Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell type-specific effect of hypoxia and platelet-derived growth factor-BB on extracellular matrix turnover and its consequences for lung remodeling.
    Karakiulakis G; Papakonstantinou E; Aletras AJ; Tamm M; Roth M
    J Biol Chem; 2007 Jan; 282(2):908-15. PubMed ID: 17099219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
    Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
    Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of Pan-Fibroblast Growth Factor Receptors Mediates Bidirectional Effects in Lung Fibrosis.
    Morizumi S; Sato S; Koyama K; Okazaki H; Chen Y; Goto H; Kagawa K; Ogawa H; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
    Am J Respir Cell Mol Biol; 2020 Sep; 63(3):317-326. PubMed ID: 32338990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic Fibroblast Growth Factor Induces Adipogenesis in Orbital Fibroblasts: Implications for the Pathogenesis of Graves' Orbitopathy.
    Schrijver B; Kooiman MA; Kasteleijn E; van Holten-Neelen C; Virakul S; Paridaens D; Peeters RP; van Hagen PM; Dalm VASH; Dik WA
    Thyroid; 2019 Mar; 29(3):395-404. PubMed ID: 30724135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.